Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

St. Luke's Hospital acquires computer-assisted surgery system from BrainLAB

BrainLAB, a manufacturer of software-driven systems for targeted, less-invasive medical treatments, announced today that St. Luke's Hospital in Cedar Rapids, Iowa, has acquired VectorVision® flex, a powerful computer-assisted surgery (CAS) system featuring Digital Lightbox© with TraumaCad(TM), a pre-operative planning and digital templating software solution.

9 Dec 2009

Spectrum Pharmaceuticals recognized as one of the Top Work Places in Orange County

Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial stage biotechnology company with a primary focus in oncology, today announced that it has been ranked by the Orange County Register as one of Orange County’s Top Work Places for 2009.

9 Dec 2009

Joint Commission awards Primary Stroke Certification for TMCA

The Medical Center of Aurora (TMCA) is proud to announce its designation as a Primary Stroke Center by The Joint Commission (TJC) effective October 1, 2009. The Disease Specific Certification has been awarded to only seven other hospitals in the state of Colorado.

9 Dec 2009

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

In a large clinical trial, nilotinib demonstrated greater efficacy over the current gold standard treatment, imatinib, in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase.

9 Dec 2009

Particle Sciences expands High Potency Compound handling capabilities

Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, has further expanded their High Potency Compound (HPC) handling capabilities through a unique relationship with IES Engineers.

9 Dec 2009

VERTICAL Phase II trial results for NHL released

The Takeda Oncology Company today reported data from a clinical trial evaluating a VELCADE based combination for patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL).

9 Dec 2009

New drug designed to stop cancer from spreading by preventing mitosis

TGen Clinical Research Services at Scottsdale Healthcare (TCRS) is the world's first clinical trials site for a new drug designed to halt cancer cell division.

9 Dec 2009

No co-pays for patients enrolled in AstraZeneca's Medicare Part D prescription savings program

AstraZeneca announced today that patients enrolled in the company's Medicare Part D prescription savings program will no longer pay co-pays for their medicines through the program.

9 Dec 2009

Human blood stem cells can be engineered to kill HIV and other chronic viral diseases

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells - a process that potentially could be used against a range of chronic viral diseases.

9 Dec 2009

New Acesis software platform improves patient safety and quality care

Acesis, the enterprise software company focused on healthcare performance improvement, today announced results from its first six months of service for the University of California, San Francisco (UCSF) Division of Hospital Medicine.

9 Dec 2009

TGen and Scottsdale Healthcare test PHA-848125ac drug for thymic cancer

The Translational Genomics Research Institute (TGen) and Scottsdale Healthcare are testing a new drug specifically for thymic cancer based on early promising results at Scottsdale Healthcare.

9 Dec 2009

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

9 Dec 2009

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab.

9 Dec 2009

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Transgenomic, Inc. announced today the launch of its SURVEYOR Scan K-RAS kit, the first in a family of mutation detection kits the company plans to offer featuring its proprietary SURVEYOR Nuclease and WAVE® HS DHPLC platform. SURVEYOR Scan technology is a novel approach to mutation detection that uses a PCR amplification reaction and hybridization to form heteroduplex DNA molecules in samples with K-RAS mutation.

9 Dec 2009

Multi-institutional study identifies potential treatment target for ovarian cancer

A multi-institutional study has identified a potential personalized treatment target for the most common form of ovarian cancer. In the December 8 issue of Cancer Cell, the research team describes finding that a gene called MAGP2 - not previously associated with any type of cancer - was overexpressed in papillary serous ovarian tumors of patients who died more quickly. They also found evidence suggesting possible mechanisms by which MAGP2 may promote tumor growth.

9 Dec 2009

Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, has completed a Phase 3 clinical trial of Lymphoseek® (NEO3-05) with positive results.

9 Dec 2009

Pfizer, Crown Bioscience team up to research and develop novel therapeutics for Asian cancers

Pfizer (PFE) and Crown Bioscience, Inc. (Crown) announced today that they have entered into a collaboration to research and develop novel therapeutics for Asian cancers. Specific treatments for Asian cancers represent an important unmet medical need as well as a significant market opportunity.

9 Dec 2009

Epizyme closes Series B financing to a total of $40 million

Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation of New Enterprise Associates (NEA) in its Series B, bringing the total financing to $40M.

9 Dec 2009

Veran Medical Technologies' SPiN Drive System receives FDA marketing clearance

Veran Medical Technologies announced today that it received clearance (K091934) from the U.S. Food and Drug Administration (FDA) to market a product for the delivery of instruments through the pulmonary tract. "Veran is excited about this clearance as it allows the company to address a huge unmet clinical need in lung cancer diagnosis and treatment," said Jerome R. Edwards, Veran president and chief executive officer.

8 Dec 2009

CombinatoRx presents encouraging results from its A2A and b2AR agonist programs for B-cell malignancies

CombinatoRx, Incorporated today announced that preclinical data from its Adenosine A2A receptor (A2A) and Beta-2 Adrenergic Receptor (b2AR) Agonist oncology programs demonstrated synergistic anti-cancer activity when combined with standard-of-care therapies in multiple myeloma and other B-cell malignancies.

8 Dec 2009

Oncology News and Research

Further Reading

St. Luke's Hospital acquires computer-assisted surgery system from BrainLAB

Spectrum Pharmaceuticals recognized as one of the Top Work Places in Orange County

Joint Commission awards Primary Stroke Certification for TMCA

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

Particle Sciences expands High Potency Compound handling capabilities

VERTICAL Phase II trial results for NHL released

New drug designed to stop cancer from spreading by preventing mitosis

No co-pays for patients enrolled in AstraZeneca's Medicare Part D prescription savings program

Human blood stem cells can be engineered to kill HIV and other chronic viral diseases

New Acesis software platform improves patient safety and quality care

TGen and Scottsdale Healthcare test PHA-848125ac drug for thymic cancer

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Multi-institutional study identifies potential treatment target for ovarian cancer

Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients

Pfizer, Crown Bioscience team up to research and develop novel therapeutics for Asian cancers

Epizyme closes Series B financing to a total of $40 million

Veran Medical Technologies' SPiN Drive System receives FDA marketing clearance

CombinatoRx presents encouraging results from its A2A and b2AR agonist programs for B-cell malignancies

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News